Dr. Vimal Prajapati

Dermatologist, Calgary, AB

Dr. Prajapati completed his dermatology residency at the University of Alberta, earning certification in both Canada and the United States. He then pursued an additional 1-year fellowship in pediatric dermatology at Harvard Medical School. Dr. Prajapati has received 20 major awards; authored 1 textbook chapter; published 43 peer-reviewed manuscripts in print or electronic format; and presented 48 abstracts at scientific meetings regionally, nationally, as well as internationally. He also conducts clinical trials for both adults and children, with participation in 69 studies as an investigator or steering committee member.

Dr. Prajapati is a Clinical Associate Professor at the University of Calgary as well as co-founder and co-director of Skin Health & Wellness Centre, Dermphi Centre, and Dermatology Research Institute. Additionally, he has started several subspecialty initiatives, including multidisciplinary pediatric morphea, pediatric scleroderma, and pediatric psoriasis clinics in Calgary as well as rapid access psoriasis and rapid access eczema clinics in Calgary plus rural outreach psoriasis and rural outreach eczema clinics Medicine Hat.

4:45 AM - 5:15 PM Joint Derm Update & SRG Session

Nov 24

Does seasonal variation impact the efficacy and safety/tolerability of a new topical retinoid in acne management?

Learning Objectives:

  1. Discuss the significance of the Polymeric Emulsion Vehicle Technology in topical retinoid formulation.
  2. Analyse the impact of winter and summer seasons on the efficacy and tolerability of a new topical retinoid formulation in acne management.

11:25 AM - 12:10 PM Open Session

Nov 25

Let’s talk GPP!

In the broad category of psoriasis lies many diseases, including the broadly known and prevalent plaque psoriasis, as well as the far less common, and rare, conditions such as guttate, inverse, erythrodermic and pustular psoriasis. Despite sharing the term psoriasis, generalized pustular psoriasis (GPP) is a distinct condition whose disease pathway is different than the far more common plaque psoriasis. This open session will serve to provide a comprehensive review of GPP, including disease mechanisms and patient prevalence/predispositions. The conversation will then dive into the burden of disease and truly call to light the unmet needs that currently exists with patients suffering with GPP. Those in attendance will gain a better understanding of this rare disease.

Learning Objectives

  1. Increase awareness of generalized pustular psoriasis (GPP) as a different and distinct condition from plaque psoriasis
  2. Raise awareness and highlight the burden of disease on patients with GPP
12:15 PM - 2:15 PM Advisory Board

Nov 25

Advancing Standard of Care in Vitiligo and Atopic Dermatitis

2:40 PM - 3:25 PM Open Session

Nov 26

I Can I Am: Reaching New Possibilities with the Canadian and American Clinical Experience with Tildrakizumab

Clinical trial data suggests what can be done (I Can), while clinical experience presents what is possible (I Am). Dr. Parbeer Grewal will provide an overview of what can be done, which will be followed by a panel discussion with Canadian dermatologist Dr. Vim Prajapati and American dermatologist Dr. George Han to understand what is possible based on real-world clinical experience with tildrakizumab through the presentation of patient cases. The session will conclude with an opportunity for the audience to pose questions to the panel.

3:30 PM - 4:15 PM (Joint Derm Update & SRG Session) Open Session

Nov 26

Challenges in treating plaque psoriasis to target: special sites and managing inadequate response

Learning Objectives:

  1. Review Canadian treat-to-target recommendations
  2. Discuss considerations involved in applying treat-to-target principles and criteria to special sites
  3. Review treatment modification strategies for patients with inadequate response to biologic treatments

3:20 PM – 3:50 PM Novartis Open Presentation

Friday APR 8, 2022

Beyond the Skin: The Feasibility and Value of Systematic Screening for Psoriatic Arthritis

Dermatologists are the gatekeeper to identifying patients with early signs of PsA. However, many dermatologists do not routinely consider screening for possible signs and symptoms of psoriatic arthritis – a common psoriasis comorbidity that causes irreversible joint damage and aggravates co-morbidities.


The data from Phase 1 of the PsA Screening Project will be presented. In an initial assessment survey of 52 Canadian dermatologists, only 17% will screen their moderate-to-severe psoriasis patients for psoriatic arthritis at every follow-up visit. When screening for PsA, only 9% of respondents rely on a validated screening questionnaire. When PsA is suspected, over 50% of dermatologists will refer to a rheumatologist reflecting a need for greater comfort in managing PsA patients in dermatology practice and when appropriate, initiating a referral to rheumatologist. The PsA Screening Project had dermatologists from across the country screen patients using 3 different tools, to establish which tool type was preferred, and what barriers exist that prevent them from adequately screening.


Session Learning Objectives:

  • Recognize the impact of frequent screening for PsA on early detection
  • Demonstrate the value of using a standardized screening tool for PsA in dermatology practice
  • Consider best practices for implementation of systematic screening to improve patient outcomes
10:40 AM - 11:00 AM Arcutis Open Presentation

Saturday APR 9, 2022

Innovations in Topical Therapy: The Role of Vehicle in Treatment Decisions

This session will present audience members with a brief overview around the importance of vehicle formulation in immunodermatologic treatment. The content of the session will focus on current topical therapies as well potential future vehicle formulations while considering the clinical implications of the differences between various vehicle formulations. The session will consider the role of vehicle formulation across different regions of the body and examine factors that may influence patient adherence to therapy.



  • To discuss the importance of vehicle in immunodermatologic treatment
  • To examine opportunities for advancements with current topical therapies
  • To consider potential future vehicle formulation(s)
4:00 PM - 7:00 PM Sun Pharma Ad Board

Saturday APR 9, 2022

SUNny Days are with you

10:30 AM - 3:00 PM Boehringer Ingelheim Advisory Board

Nov 27

Boehringer Ingelheim Advisory Board